美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Versartis Inc

7.14

0.0000

成交量：- -

成交額：- -

市值：4,312.64萬

市盈率：-6.81

高：7.14

開：7.14

低：7.14

收：7.14

52周最高：7.14

52周最低：1.14

股本：604.01萬

流通股本：604.01萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-1.0488

每股收益(LYR):-2.4123

淨資產收益率：--

總資產收益率：--

市淨率：0.63

市盈率(LYR):-2.96

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Versartis Inc

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.versartis.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Versartis, Inc.是一家發展階段的公司，於2008年12月10日在特拉華州成立。公司是一家以內分泌為重點的生物製藥公司，最初為生長激素缺乏（或生長激素缺乏症），一種孤兒病開發其新穎的長效重組人生長激素——VRS-317。目前的重組人生長激素（rhGH）的一個關鍵限制產品是他們多年強加每天注射的負擔，往往造成依從性差，這反過來又可以導致生長激素缺乏症患者最理想的治療效果。儘管有此限制，全球年銷售額從目前銷售的重組人生長激素產品在過去5年每年約6％的增長到2012年超過30億。VRS -317的目的是通過要求顯著較少的注射以減少日常處理的負擔，有可能改善合規性和治療效果。公司的第一個VRS- 317的目標適應是小兒生長激素缺乏症，它代表一個約15億的現有市場機會。Versartis目前正在進行小兒生長激素缺乏症的臨床試驗中，公司正在評估每周、每半月和每月給藥方案的2a階段。Versartis為成人生長激素缺乏症、特發性矮小（或ISS）發展VRS -317，這是一種原因不明的身材矮小特納綜合征，這是女性的X染色體赤字或刪除。成人生長激素缺乏症，ISS和特納氏綜合症在一起佔全球重組人生長激素市場的約30％。Versartis對VRS- 317有全球性的權利。如果VRS -317被批准后並給予了高度集中的處方基地，Versartis打算在美國和加拿大以及潛在的其他地區使自己的專業銷售隊伍商業化。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/VSAR/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"VSAR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VSAR\",,,,,undefined,":{"symbol":"VSAR","market":"US","secType":"STK","nameCN":"Versartis Inc","latestPrice":7.14,"timestamp":1539633599999,"preClose":7.14,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":6040109,"shares":6040109,"eps":-1.048764,"marketStatus":"休市中","change":0,"latestTime":"10-15 15:59:59 EDT","open":7.14,"high":7.14,"low":7.14,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.048764,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"symbolChange":{"newSymbol":"ARAV","executeDate":"2018-10-16"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":7.14,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VSAR\",,,,,undefined,":{"symbol":"VSAR","floatShares":6040109,"roa":"--","roe":"--","lyrEps":-2.412257,"shares":6040109,"dividePrice":0,"high":7.14,"amplitude":0,"preClose":7.14,"low":7.14,"week52Low":1.14,"pbRate":"0.63","week52High":7.14,"institutionHeld":0,"latestPrice":7.14,"eps":-1.048764,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.048764,"open":7.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VSAR\",params:#limit:5,,,undefined,":[{"date":"2018-10-16","symbol":"VSAR","newSymbol":"ARAV","type":"symbolChange","dateTimestamp":1539662400000},{"market":"US","date":"2018-08-07","symbol":"VSAR","fiscalQuarterEnding":"2018/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1533614400000,"reportTimeType":"","actualEps":-0.27},{"market":"US","date":"2018-05-08","symbol":"VSAR","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"","actualEps":-0.25},{"market":"US","date":"2018-03-01","symbol":"VSAR","fiscalQuarterEnding":"2017/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1519880400000,"reportTimeType":"","actualEps":0.87},{"market":"US","date":"2017-10-26","symbol":"VSAR","fiscalQuarterEnding":"2017/09","expectedEps":-0.68,"name":null,"time":"","type":"earning","dateTimestamp":1508990400000,"reportTimeType":"","actualEps":-1.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VSAR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VSAR\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.versartis.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Versartis, Inc.是一家發展階段的公司，於2008年12月10日在特拉華州成立。公司是一家以內分泌為重點的生物製藥公司，最初為生長激素缺乏（或生長激素缺乏症），一種孤兒病開發其新穎的長效重組人生長激素——VRS-317。目前的重組人生長激素（rhGH）的一個關鍵限制產品是他們多年強加每天注射的負擔，往往造成依從性差，這反過來又可以導致生長激素缺乏症患者最理想的治療效果。儘管有此限制，全球年銷售額從目前銷售的重組人生長激素產品在過去5年每年約6％的增長到2012年超過30億。VRS -317的目的是通過要求顯著較少的注射以減少日常處理的負擔，有可能改善合規性和治療效果。公司的第一個VRS- 317的目標適應是小兒生長激素缺乏症，它代表一個約15億的現有市場機會。Versartis目前正在進行小兒生長激素缺乏症的臨床試驗中，公司正在評估每周、每半月和每月給藥方案的2a階段。Versartis為成人生長激素缺乏症、特發性矮小（或ISS）發展VRS -317，這是一種原因不明的身材矮小特納綜合征，這是女性的X染色體赤字或刪除。成人生長激素缺乏症，ISS和特納氏綜合症在一起佔全球重組人生長激素市場的約30％。Versartis對VRS- 317有全球性的權利。如果VRS -317被批准后並給予了高度集中的處方基地，Versartis打算在美國和加拿大以及潛在的其他地區使自己的專業銷售隊伍商業化。","exchange":"NASDAQ","name":"Versartis Inc","nameEN":"Versartis"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"VSAR\",market:\"US\",,,undefined,":null}}